Orexo announces that the condition for early redemption of its existing bonds has been fulfilled

2024-04-02

UPPSALA, Sweden, April 2, 2024 /PRNewswire/ -- On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 (ISIN SE0015193958) (the "Existing Bonds"). The early redemption was conditional upon that settlement of the Company's issue of new senior secured social bonds with a tenor of four years has occurred, which is further described in the Company's press release on March 13, 2024. This condition has been fulfilled and the early redemption is therefore no longer conditional. Hence, the early redemption will occur on April 11, 2024, and the redemption amount will be paid to each person who is registered as owner of Existing Bonds in the debt register maintained by Euroclear Sweden at the end of business on April 4, 2024. For further information on the early redemption, see the Company's press release on March 13, 2024, and the notice of early redemption which is available on the Company's website. For further information please contact: Nikolaj Sørensen, President and CEO Fredrik Järrsten, EVP and CFO Lena Wange, IR & Communications Director Tel: +46 (0)18 780 88 00 E-mail: ir@orexo.com About Orexo Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US. For more information about Orexo please visit . You can also follow Orexo on X, LinkedIn, and YouTube. The information was sent for publication, through the agency of the contact person set out above, on April 2, 2024, at 1.15 pm CET. This information was brought to you by Cision The following files are available for download: View original content: SOURCE Orexo Company Codes: Stockholm:ORX, OTC-PINK:ORXOY, ISIN:SE0000736415, RICS:ORX.ST, OTCQX:ORXOY

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构